A Phase II (BRF113710) single-arm, open-label study of GSK2118436 (dabrafenib) in BRAF mutant metastatic melanoma

Trial Profile

A Phase II (BRF113710) single-arm, open-label study of GSK2118436 (dabrafenib) in BRAF mutant metastatic melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Dabrafenib (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BREAK-2
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results of 5 year landmark analysis for phase II BREAK 2 (data cutoff date 17 Jun 2016) and phase III BREAK 3 (data cutoff date 6 Sep 2016) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2014 Planned End Date changed from 1 Aug 2012 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top